Risks to Your Liver (Hepatotoxicity) : How do ARV drugs cause it?

A Smart + Strong Site
Subscribe to:
POZ magazine
Risks to Your Liver (Hepatotoxicity)
en español

How do ARV drugs cause it?

Even though HIV drugs are intended to do your health good, the liver recognizes these medications as toxic compounds. After all, they are not naturally produced by the body and do contain some chemicals that could potentially cause damage to your body. Working with the kidneys and other organs, the liver processes these drugs to render them safer. In the process, the liver can become "overworked," which can lead to liver damage.

There are actually two ways that HIV meds can lead to liver damage:

Direct damage to liver cells:

Liver cells, called hepatocytes, play a vital role in the functioning of the liver. If these cells begin working too hard to remove chemicals from the blood, or if they are harmed by other infections (e.g., hepatitis C virus), abnormal chemical reactions can occur that can damage these cells. There are actually three ways in which this can happen:

  • Taking a very high dose of a drug. If you were to swallow a high dose of an ARV drug or another medication (i.e., taking many pills when you are supposed to take one or two), this can cause immediate and sometimes severe damage to liver cells. Almost any drug, if an overdose is taken, can cause this type of liver damage.
  • Taking standard doses of medication for a long period of time. If you take medications on a regular basis for a long period of time, there is also a risk of damage to these liver cells. This usually occurs after several months or years of taking certain medications. Protease inhibitors have the ability to cause damage to liver cells if they are used for long periods of time.
  • An allergic reaction. When we hear the term "allergic reaction," we often think of itchy skin or runny eyes. However, allergic reactions can also take place in the liver. If you are allergic to a particular drug, your immune system can cause your liver to become inflamed as a result of interactions between key liver proteins and the drug. If the drug is not stopped, the inflammation can worsen and can cause serious damage to the liver. Two HIV drugs known to cause such allergic reactions (sometimes referred to as "hypersensitivity") in HIV-positive people are Ziagen (abacavir) and Viramune (nevirapine). Allergic reactions such as these usually occur within a few weeks or months after the drug is started and either may or may not be accompanied by other allergy-related symptoms (e.g., fever or a rash).
  • Non-allergic liver damage. Some drugs can cause liver damage without an allergic reaction or use at high doses. Two particular HIV drugs that can cause serious liver damage, though in relatively small numbers of people, are Aptivus (tipranavir) and Prezista (darunavir). People with hepatitis B virus (HBV) or hepatic C virus (HCV).
Lactic Acidosis:
Nucleoside reverse transcriptase inhibitors (NRTIs) are not processed by they liver; they are removed from the bloodstream and from the body by the kidneys. Thus, many experts once speculated that these drugs would not likely cause damage to the liver. But, we now know that these drugs can damage "cellular mitochondria," the "powerhouses" inside cells that convert nutrients into energy. This can cause levels of lactate, a cellular waste product, to become elevated. If these levels become too high, a condition called lactic acidosis can occur, which can result in liver problems, including a buildup of fat in and around the liver and liver inflammation.

back next

Last Revised: June 23, 2011

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

Liver updates
Hep C Genotype 3 Treatment Results Same in HIV Coinfection

Waistlines Tied to Liver Stiffness in Women With Hep C

Women Spontaneously Clear Hep C Better Than Men

HIV/Hep B Coinfection Responds Very Well to Viread

Liver Cancer Deaths Double in Two Decades

Conditions Outside of AIDS Pose Significant Threat to People With HIV

HIV and Hepatitis C Coinfection Raises Cognitive Impairment Risk for Men

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

HIV Meds and Alcohol Not a Toxic Mix, Yet Many Skip Doses While Drinking

Multivitamins: More Not Better When HIV Meds are Being Used

Obesity Linked to Chronic Non-AIDS Health Problems in HIV+ People

HIV Therapy Helps Reduce Risk of Non-AIDS Illnesses

Sofosbuvir (GS-7977) Shows Promise in HIV/Hep C-Coinfected People

Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease

Interferon, High Blood Pressure May be Risk to Vision

CDC Officially Recommends One-Time Hep C Tests for All Baby Boomers

Despite ARV Therapy, HIV/Hep C Patients Face Increased Risk of Serious Liver Disease

Hep C Treatment Failure Can Still Mean Less Liver Inflammation

HIV/Hep C Coinfection and Each Virus by Itself Increase Hip Fracture Risk

1 in 4 Los Angeles Homeless Have Hep C

Hep B Prevalence in U.S. Is Double the CDC’s Estimate

Curative Hep C Treatment Benefits Non-Liver Health and Survival in HIV

CDC Set to Recommend One-Time Hep C Tests for All Baby Boomers

Hep C Risk Highest for Baby Boomers, but Most Haven’t Been Tested

Depression Is Common and Needs Managing Before and During Hep C Interferon Treatment

Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C

Facebook to Promote Organ Donation; May Benefit People With Hep C or HIV

FDA to Docs: Best to Avoid Victrelis With Norvir-Boosted HIV Protease Inhibitors

Revised U.S. Guidelines Make Key HIV and Hep C Treatment Recs

Clearing or Curing Acute HCV Does Not Protect Against Reinfection

HCV Testing, Diagnosis Being Overlooked in People With HIV

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

ARV Liver Toxicity in HIV/Hep C Coinfected Patients on the Decline

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

Incivek, Victrelis Studies Hint at Superior Cure Rates in HIV/HCV Coinfection

Hep C Now Trumps HIV as Cause of Death in U.S.

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Many at Risk for Hep B in U.S. Aren't Getting Vaccinated

Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV

Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV

Victrelis Keeps Hep C Viral Load Undetectable for 24 Weeks in 7 of 10 Coinfected Patients

Despite High CD4s, Unchecked Viral Load Linked to Higher AIDS Risk

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

New Hep C Treatment Guidelines Spell Out Incivek and Victrelis Use

Hepatitis C in the U.S. May Be Underestimated by Over a Million

BMS Drug Boosts Hep C Cure Rates

Coffee Helps Minimize Hepatitis C Treatment Side Effects

HIV Linked to False Negative Hep C Results Using Some Rapid Assays

DRACO: A Broad-Spectrum Therapy Against Multiple Viruses

Doubled Risk of Death Among Publicly Insured People With HIV in U.S.

Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility

WHO World Hepatitis Day Report: One in 12 Living With Chronic Hep B or C

Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients

Hepatitis C Sexually Transmitted between HIV-Positive Men

Survival Benefit Among HIV-Positive Liver, Kidney Transplant Recipients

HIV, Hep C Drug Development Pipeline is 'Robust,' Says Report

Survey Finds Support for Universal Hep C Testing

Liver Damage Increases Tenofovir-Induced Kidney Impairment Risk

> More Treatment News

Search for news stories about this topic

Lesson Index
Collapse All | Up One Level

Tell us what you think
Have you visited your health care provider within the last 4 months?

AIDSmeds Reader Survey

more surveys

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.